Hereditary angioedema in childhood: An approach to management

被引:15
|
作者
Ebo D.G. [1 ]
Verweij M.M. [2 ]
De Knop K.J. [1 ]
Hagendorens M.M. [2 ]
Bridts C.H. [1 ]
De Clerck L.S. [1 ]
Stevens W.J. [1 ]
机构
[1] Department of Immunology, Allergology and Rheumatology, University Hospital Antwerp, Antwerp University, 2610 Antwerp
[2] Department of Paediatrics, University Hospital Antwerp, Antwerp University, Antwerp
关键词
antifibrinolytic-agents; therapeutic use; bradykinin-B2-receptor-; antagonists; children; complement-C1r-inhibitors; ecallantide; hereditary-angioedema; pathogenesis; prevention; treatment; icatibant; kallikrein-inhibitors; research-and-development; testosterone-congeners;
D O I
10.2165/11532590-000000000-00000
中图分类号
学科分类号
摘要
Hereditary angioedema (HAE) is an inherited disorder characterized by recurrent, circumscribed, non-pitting, non-pruritic, and rather painful subepithelial swelling of sudden onset, which fades during the course of 4872 hours, but can persist for up to 1 week. Lesions can be solitary or multiple, and primarily involve the extremities, larynx, face, esophagus, and bowel wall. Patients with HAE experience angioedema because of a defective control of the plasma kinin-forming cascade that is activated through contact with negatively charged endothelial macromolecules leading to binding and auto-activation of coagulation factor XII, activation of prekallikrein to kallikrein by factor XIIa, and cleavage of high-molecular-weight kininogen by kallikrein to release the highly potent vasodilator bradykinin. Three forms of HAE have currently been described. Type I and type II HAE are rare autosomal dominant diseases due to mutations in the C1-inhibitor gene (SERPING1). C1-inhibitor mutations that cause type I HAE occur throughout the gene and result in truncated or misfolded proteins with a deficiency in the levels of antigenic and functional C1-inhibitor. Mutations that cause type II HAE generally involve exon 8 at or adjacent to the active site, resulting in an antigenically intact but dysfunctional mutant protein. In contrast, type III HAE (also called estrogen-dependent HAE) is characterized by normal C1-inhibitor activity. The diagnosis of HAE is suggested by a positive family history, the absence of accompanying pruritus or urticaria, the presence of recurrent gastrointestinal attacks of colic, and episodes of laryngeal edema. Estrogens may exacerbate attacks, and in some patients attacks are precipitated by trauma, inflammation, or psychological stress. For type I and type II HAE, diminished C4 concentrations are highly suggestive for the diagnosis. Further laboratory diagnosis depends on demonstrating a deficiency of C1-inhibitor antigen (type I) in most kindreds, but some kindreds have an antigenically intact but dysfunctional protein (type II) and require a functional assay to establish the diagnosis. There are no particular laboratory findings in type III HAE.Prophylactic administration of either 17α-alkylated androgens or synthetic antifibrinolytic agents has proven useful in reducing the frequency or severity of attacks. Plasma-derived C1-inhibitor concentrate, recombinant C1-inhibitor, ecallantide (DX88; a plasma kallikrein inhibitor) and icatibant (a bradykinin B2 receptor antagonist) have demonstrated significant efficacy in the treatment of acute attacks, whereas the C1-inhibitor concentrate has also provided a significant benefit as long-term prophylaxis. However, these drugs are not licensed in all countries and are not always readily available. © 2010 Adis Data Information BV. All rights reserved.
引用
收藏
页码:257 / 268
页数:11
相关论文
共 50 条
  • [31] HEREDITARY ANGIOEDEMA - A DECADE OF MANAGEMENT WITH STANOZOLOL
    SHEFFER, AL
    FEARON, DT
    AUSTEN, KF
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1987, 80 (06) : 855 - 860
  • [32] Recent Advances in the Management of Hereditary Angioedema
    Hemperly, Stephen E.
    Agarwal, Niti Sardana
    Xu, Ying-Yang
    Zhi, Yu-Xiang
    Craig, Timothy J.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2013, 113 (07): : 546 - 555
  • [33] MANAGEMENT PLAN FOR PATIENTS WITH HEREDITARY ANGIOEDEMA
    Gower, R. G.
    Levitch, E. S.
    Brenner, M. J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A96 - A96
  • [34] Current Management Options for Hereditary Angioedema
    Konrad Bork
    Current Allergy and Asthma Reports, 2012, 12 : 273 - 280
  • [35] DIAGNOSIS AND MANAGEMENT OF HEREDITARY ANGIOEDEMA (HAE)
    ATKINSON, JP
    ANNALS OF ALLERGY, 1979, 42 (06): : 349 - 351
  • [36] Management and Prevention of Hereditary Angioedema Attacks
    Lumry, William R.
    AMERICAN JOURNAL OF MANAGED CARE, 2013, 19 (07): : S111 - S118
  • [37] Hereditary angioedema: Prophylaxis management in the puerperium
    Hawthorne, LA
    Gooi, HC
    ANAESTHESIA, 1996, 51 (03) : 283 - 283
  • [38] Revolutionizing hereditary angioedema management: a breakthrough
    Das, Soumyajit
    Khatib, Mahalaqua N.
    Banda, Godfrey T.
    Gaidhane, Shilpa
    Sharma, Divya
    Sharma, Rakesh K.
    Arora, Mithhil
    Rustagi, Sarvesh
    Satapathy, Prakasini
    Sah, Ranjit
    INTERNATIONAL JOURNAL OF SURGERY OPEN, 2024, 62 (04) : 491 - 492
  • [39] Management plan for patients with hereditary angioedema
    Gower, R.
    Levitch, E.
    Brenner, M.
    ALLERGY, 2012, 67 : 358 - 358
  • [40] Perioperative management for patients with hereditary angioedema
    Williams, Anesu H.
    Craig, Timothy J.
    ALLERGY & RHINOLOGY, 2015, 6 (01) : E50 - E55